Search Results for: positive

By Kuldip K. Ambastha and Anil K. Ambastha On Monday, December 9, 2019, big news emerged in the mergers & acquisitions field in terms of Merck & Co., Inc. (MRK) buying ArQule, Inc. (ARQL) and Sanofi SA (SNY) buying Synthorx Inc. (THOR). Both Merck and Sanofi bought the smaller companies to enhance their capabilities in …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 9-13, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha On Thursday, December 5, 2019, there was “a tale of two cities,” to quote Charles Dickens. In the biotech arena, SAGE (Sage Therapeutics, Inc.) and AUPH (Aurinia Pharmaceuticals Inc.) were big movers. Sage Therapeutics delivered -59.7% for the day, while Aurinia Pharmaceuticals returned 78.8%. SAGE-217 is a …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 2-6, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha During this trading week, JP Morgan Chase & Co. (JPM) was a star performer. Specifically, the company delivered on many fronts, in terms of strong underwriting data, an increase in mortgage banking activities, significant bond trading income, substantial wholesale and credit card loans, and positive home lending …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 14-18, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 9-13, 2019”